Dengue research opportunities in the Americas

Journal of Infectious Diseases

Volumn 206, Issue 7, 2012, Pages 1121-1127

  Laughlin, Catherine A ^a   Morens, David M ^a   Cassetti, M Cristina ^a   Costero Saint Denis, Adriana ^a   San Martin, Jose Luis ^b   Whitehead, Stephen S ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Pan American Health Organization   (Costa Rica)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DENGUE VACCINE; VIRUS RNA;

AEDES AEGYPTI; BLOOD ANALYSIS; CLINICAL EVALUATION; DENGUE; DENGUE VIRUS; DIAGNOSTIC PROCEDURE; DISEASE CARRIER; DRUG EFFICACY; GEOGRAPHY; HEALTH CARE SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGY; INFECTION CONTROL; MEDICAL RESEARCH; PATHOGENICITY; POINT OF CARE TESTING; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RNA ANALYSIS; SENSITIVITY AND SPECIFICITY; UNITED STATES; VIRUS REPLICATION;

AMERICAS; ANIMALS; ANOPHELES; CLINICAL TRIALS AS TOPIC; DENGUE; DENGUE VACCINES; DENGUE VIRUS; ENDEMIC DISEASES; HUMANS; INSECT VECTORS;

EID: 84866142086     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis351     Document Type: Review

References (51)

1. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Mi-crobiol 2002; 10:100-3. (Pubitemid 34119347)
2. Vasilakis N, Weaver SC. The history and evolution of human dengue emergence. Adv Virus Res 2008; 72:1-76.
3. du Tertre JB. Histoire generale des Antilles habitees par les Francois. In: Jolie T, ed. Paris, 1667-71.
4. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 11:480-96. (Pubitemid 28379096)
5. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994; 19:500-12. (Pubitemid 24286955)
6. Pan American Health Organization. Resolution CD44.R9. Vol. 55th Session of the Regional Committee. Washington, DC, 2003.
7. Yu IM, Zhang W, Holdaway HA, et al. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science 2008; 319:1834-7. (Pubitemid 351451592)
8. Balsitis SJ, Coloma J, Castro G, et al. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immu-nostaining. Am J Trop Med Hyg 2009; 80:416-24.
9. Rodenhuis-Zybert IA, Wilschut J, Smit JM. Dengue virus life cycle: viral and host factors modulating infectivity. Cell Mol Life Sci 2010; 67:2773-86.
10. van der Schaar HM, Rust MJ, Chen C, et al. Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. PLoS Pathog 2008; 4:e1000244.
11. Zaitseva E, Yang ST, Melikov K, Pourmal S, Chernomordik LV. Dengue virus ensures its fusion in late endosomes using compartment-specific lipids. PLoS Pathog 2010; 6:pii e1001131.
12. Filomatori CV, Lodeiro MF, Alvarez DE, Samsa MM, Pietrasanta L, Gamarnik AV. A 5′ RNA element promotes dengue virus RNA synthesis on a circular genome. Genes Dev 2006; 20:2238-49.
13. Welsch S, Miller S, Romero-Brey I, et al. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe 2009; 5:365-75.
14. Samsa MM, Mondotte JA, Iglesias NG, et al. Dengue virus capsid protein usurps lipid droplets for viral particle formation. PLoS Pathog 2009; 5:e1000632.
15. Ashour J, Laurent-Rolle M, Shi PY, Garcia-Sastre A. NS5 of dengue virus mediates STAT2 binding and degradation. J Virol 2009; 83:5408-18.
16. Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J Virol 1999; 73:783-6. (Pubitemid 28565427)
17. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 2006; 80:10208-17. (Pubitemid 44522614)
18. Fischer DB, Halstead SB. Observations related to pathogenesis of dengue hemorrhagic fever. V. Examination of agspecific sequential infection rates using a mathematical model. Yale J Biol Med 1970; 42:329-49.
19. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003; 60:421-67. (Pubitemid 137639381)
20. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 2007; 104:9422-7. (Pubitemid 47185795)
21. Balsitis SJ, Williams KL, Lachica R, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 2010; 6:e1000790.
22. Rothman AL. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr Top Microbiol Immunol 2010; 338:83-98.
23. Beltramello M, Williams KL, Simmons CP, et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010; 8:271-83.
24. Lai CY, Tsai WY, Lin SR, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 2008; 82:6631-43.
25. Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328:745-8.
26. Peeling RW, Artsob H, Pelegrino JL, et al. Evaluation of diagnostic tests: dengue. Nat Rev Microbiol 2010; 8:S30-8.
27. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49(suppl 2):1S-29S.
28. Srikiatkhachorn A, Green S. Markers of dengue disease severity. Curr Top Microbiol Immunol 2010; 338:67-82.
29. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9. (Pubitemid 30049026)
30. Nicholson CO, Costin JM, Rowe DK, et al. Viral entry inhibitors block dengue antibody-dependent enhancement in vitro. Antiviral Res 2011; 89:71-4.
31. Sessions OM, Barrows NJ, Souza-Neto JA, et al. Discovery of insect and human dengue virus host factors. Nature 2009; 458:1047-50.
32. London NR, Li DY. Robo4-dependent Slit signaling stabilizes the vas-culature during pathologic angiogenesis and cytokine storm. Curr Opin Hematol 2011; 18:186-90.
33. Nene V, Wortman JR, Lawson D, et al. Genome sequence of Aedes aegypti, a major arbovirus vector. Science 2007; 316:1718-23. (Pubitemid 46988541)
34. Turley AP, Moreira LA, O'Neill SL, McGraw EA. Wolbachia infection reduces blood-feeding success in the dengue fever mosquito, Aedes aegypti. PLoS Negl Trop Dis 2009; 3:e516.
35. Saavedra-Rodriguez K, Strode C, Flores Suarez A, et al. Quantitative trait loci mapping of genome regions controlling permethrin resistance in the mosquito Aedes aegypti. Genetics 2008; 180:1137-52.
36. Rapley LP, Johnson PH, Williams CR, et al. A lethal ovitrap-based mass trapping scheme for dengue control in Australia: II. Impact on populations of the mosquito Aedes aegypti. Med Vet Entomol 2009; 23:303-16.
37. Webster DP, Farrar J, Rowland-Jones S. Progress towards a dengue vaccine. Lancet Infect Dis 2009; 9:678-87.
38. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29:7229-41.
39. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine 2011; 29:7242-50.
40. Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. Dengue 2 PDK-53 virus as a chimeric carrier for tetrava-lent dengue vaccine development. J Virol 2003; 77:11436-47. (Pubitemid 37271642)
41. Clements DE, Coller BA, Lieberman MM, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010; 28:2705-15.
42. Schmitz J, Roehrig J, Barrett A, Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011; 29:7276-84.
43. Beckett CG, Tjaden J, Burgess T, et al. Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial. Vaccine 2011; 29:960-8.
44. Simmons M, Burgess T, Lynch J, Putnak R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 2010; 396:280-8.
45. Maves RC, Ore RM, Porter KR, Kochel TJ. Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. Vaccine 2011; 29:2691-6.
46. White LJ, Parsons MM, Whitmore AC, Williams BM, de Silva A, Johnston RE. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J Virol 2007; 81:10329-39. (Pubitemid 47463308)
47. Raviprakash K, Wang D, Ewing D, et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 2008; 82:6927-34. (Pubitemid 351977713)
48. Giles B, Ross TM. A computationally optimized broadly reactive antigen (COBRA) based H5n1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 2011; 29:3043-54.
49. Guy B, Saville M, Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 2010; 6:696-705.
50. Sun W, Cunningham D, Wasserman SS, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in fla-vivirus-naive adults. Hum Vaccin 2009; 5:33-40.
51. McArthur JH, Durbin AP, Marron JA, et al. Phase I clinical evaluation of rDEN4Delta30-200, 201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg 2008; 79:678-84.